Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (31-40 of 391) with videos related to

Pageof 40
Sort By:
Advances in Therapy|May 24, 2019
Management of Fibrosing Interstitial Lung DiseasesToby M Maher, Wim Wuyts
Current Opinion in Pulmonary Medicine|July 4, 2024
The future of clinical trials in idiopathic pulmonary fibrosisPaolo Spagnolo, Toby M Maher
The Lancet. Respiratory Medicine|April 29, 2014
Respiratory microbiome in IPF: cause, effect, or biomarker?Philip L Molyneaux, Toby M Maher
American Journal of Respiratory and Critical Care Medicine|December 20, 2023
Gazing into the Proteomic Crystal Ball: Predicting Survival in Idiopathic Pulmonary FibrosisJoyce S Lee, Toby M Maher
Respirology (Carlton, Vic.)|June 14, 2018
Could quality be the key in connective tissue disease-associated interstitial lung disease?Philip L Molyneaux, Toby M Maher
European Respiratory Review : an Official Journal of the European Respiratory Society|March 25, 2026
Progressive pulmonary fibrosis: the importance of identification and interventionPhilip L Molyneaux, Toby M Maher
Drugs & Aging|March 14, 2019
Idiopathic Pulmonary Fibrosis: New and Emerging Treatment OptionsRichard J Hewitt, Toby M Maher
American Journal of Respiratory and Critical Care Medicine|October 15, 2016
Reply: Daily Home Spirometry: A New Milestone in the Field of Pulmonary FibrosisAnne-Marie Russell, Toby M Maher,
F1000Prime Reports|March 27, 2014
The treatment of idiopathic pulmonary fibrosisHannah V Woodcock, Toby M Maher
Drug Design, Development and Therapy|October 12, 2012
Current and novel drug therapies for idiopathic pulmonary fibrosisHuzaifa I Adamali, Toby M Maher
Pageof 40

Showing results (31-40 of 391) with videos related to

Sort By:
Pageof 40
Advances in Therapy|May 24, 2019
Management of Fibrosing Interstitial Lung DiseasesToby M Maher, Wim Wuyts
Current Opinion in Pulmonary Medicine|July 4, 2024
The future of clinical trials in idiopathic pulmonary fibrosisPaolo Spagnolo, Toby M Maher
The Lancet. Respiratory Medicine|April 29, 2014
Respiratory microbiome in IPF: cause, effect, or biomarker?Philip L Molyneaux, Toby M Maher
American Journal of Respiratory and Critical Care Medicine|December 20, 2023
Gazing into the Proteomic Crystal Ball: Predicting Survival in Idiopathic Pulmonary FibrosisJoyce S Lee, Toby M Maher
Respirology (Carlton, Vic.)|June 14, 2018
Could quality be the key in connective tissue disease-associated interstitial lung disease?Philip L Molyneaux, Toby M Maher
European Respiratory Review : an Official Journal of the European Respiratory Society|March 25, 2026
Progressive pulmonary fibrosis: the importance of identification and interventionPhilip L Molyneaux, Toby M Maher
Drugs & Aging|March 14, 2019
Idiopathic Pulmonary Fibrosis: New and Emerging Treatment OptionsRichard J Hewitt, Toby M Maher
American Journal of Respiratory and Critical Care Medicine|October 15, 2016
Reply: Daily Home Spirometry: A New Milestone in the Field of Pulmonary FibrosisAnne-Marie Russell, Toby M Maher,
F1000Prime Reports|March 27, 2014
The treatment of idiopathic pulmonary fibrosisHannah V Woodcock, Toby M Maher
Drug Design, Development and Therapy|October 12, 2012
Current and novel drug therapies for idiopathic pulmonary fibrosisHuzaifa I Adamali, Toby M Maher
Pageof 40